Enovis 3rd Quarter 2026 Earnings Call - ENOVIS CORP

Explicit Guidance:

• FY2026 Revenue: Narrowed range to $2.32–$2.35 billion.
• FY2026 Organic Growth: Expected to be approximately 5%.
• FY2026 Adjusted EBITDA: Increased range to $428–$438 million.
• FY2026 Adjusted EPS: Increased range to $3.58–$2.79 (Note: Transcript states "increasing... to $3.58 to $2.79"; context suggests range expansion/revision, likely $2.69–$2.79 or similar, but exact numbers as transcribed are noted).
• FY2026 Q4 Expectations: Modest acceleration in both segments driven by harvest, shoulder growth, Nebula conversions, and new P&R products; assumes Q3 procedural environment holds with typical seasonality.
• FY2027 Free Cash Flow (FCF) Conversion: Guidance updated to a step-up to at least 50% conversion for next year, targeting $100 million in cash generation.
• FY2026 FCF Conversion: Maintaining target of greater than 25% for the full year.
• Q4 2026 Non-GAAP Adjustments: Includes $4 million incremental investment in enabling technology R&D talent and $1 million negative currency impact.
• Balance Sheet Leverage: Post-transaction leverage expected to step up by 0.5x; target range remains 2.5–3.5x.

Business-Segment Outlook:

• Recon (Orthopedics):
  • US Market: Expecting high single-digit growth in Q4; momentum building in hips and knees despite market volatility.
  • Shoulders: Strong performance in Q3 with double-digit international growth; expanding Arvus shoulder launch into new geographies; expecting continued market share gains as a global No. 2 player.
  • Hips and Knees: Nebula remains the top-selling stem; over 80% of new instrumentation sets going to competitive users; ASC penetration climbing (approx. 25% for knees, 20%+ for hips, high teens for shoulders).
  • International: Western Europe dynamics remain challenging; Arvus Shoulder cases completed in Europe; Lima integration contributing to mix and margin improvements.
  • Foot and Ankle: Volatile quarterly performance but underlying portfolio strength; expected to grow into high single-digit range over time with new innovations launching late 2026 and 2027.
• P&R (Rehabilitation):
  • US: Solid above-market performance; Manifuse driving double-digit growth in regenerative products; tailwinds from the No Pain Act.
  • International: Challenged, specifically in France and Germany; teams executing to counter dynamics.
  • Product Portfolio: >50% of portfolio growing mid-single-digits or greater; MotionMD software maintaining 99% customer satisfaction with high stickiness.
• Essential Robotics (Acquisition):
  • Timeline: Deal expected to close by end of 2026.
  • Product Launch: Knee robot expected to market within two years (approx. FY2028); shoulder robot to follow soon thereafter.
  • Strategy: Focus on developing an integrated ecosystem of enabling technology, planning, navigation, and robotics; no specific go-to-market strategy disclosed yet.

Market and Competitive Outlook:

• Competitive Environment: Market described as "choppy" and "volatile" with potential patient deferrals (co-pays, deductibles) and surgical schedule cancellations.
• Share Gain Focus: Management prioritizes gaining market share over volume growth; utilizing sales force training, account segmentation, and disciplined pricing to counter macro headwinds.
• Key Differentiators: Nebula with impactor/triple-tapered collar cited as critical for share gains; Arvus providing enabling tech to complement existing portfolios (Lima, Legacy, Ovis).
• ASC Trend: Continued strategic channel expansion; procedures shifting toward ASCs, particularly for knees.

Macro / Industry Outlook:

• Currency: Negative impact of 100 basis points to international growth due to FX headwinds in Q3; $1 million negative impact expected in Q4.
• Geopolitical/Tariffs:
  • Middle East conflict: 100 bps headwind to international growth (approx. 40 bps to total growth); $3 million inflationary pressure on raw materials/freight.
  • Tariffs: $8 million in refunds recognized in Q3; teams working on mitigation for future inflationary pressure.
• Regulatory: EUMDR (EU Medical Device Regulation) compliance costs expected to step down year-over-year, aiding margin expansion.
• Broader Economy: Management views the market as dynamic and volatile, focusing on "controllables" rather than macro drivers.

Strategic Initiatives:

• Acquisition of Essential Robotics:
  • Binding offer accepted on Sept 1st; Works Council consultation completed.
  • Investment: Investing to secure talent and technology for pre-close integration.
  • Impact: Anticipated to be a "meaningful contributor" to sustained above-market growth; de-risking the robotics program.
• Capital Allocation:
  • Share Repurchases: Board authorized $200 million new buyback program; execution will be opportunistic and disciplined while maintaining 2.5–3.5x leverage.
  • Debt Reduction: Committed to improving balance sheet but prioritizing growth-driving capital allocation.
  • CapEx: Instrument deployment weighted to first half; CapEx as % of sales expected to tick down over next couple of years despite growth investments in Recon.

Risks and Headwinds to Outlook:

• Market Volatility: Uncertainty in procedural volumes due to patient willingness to pay and hospital schedule disruptions.
• Geopolitical Risk: Ongoing conflict in the Middle East impacting supply chain costs and international demand.
• Integration Risk: Uncertainties associated with the Essential Robotics acquisition integration and talent retention.
• Competitive Landscape: New competitor launches (e.g., knee systems) and lack of impactor solutions from rivals could influence short-term dynamics.
• Currency Fluctuations: Continued FX headwinds could impact reported growth rates.

Management Tone on the Future:

• Confidence Level: High confidence in the long-term growth strategy, cash generation, and ability to gain market share despite a "choppy" market.
• Strategic Shift: Viewing the Essential Robotics acquisition as an "exciting inflection point" to solve known problems and anticipate workflow evolution.
• Hedges: Management explicitly avoids guiding on specific anatomy growth (hips/knees) due to market volatility; emphasizes "harvest" and "seasonality" for Q4 rather than volume assumptions.
• Communication: Will provide full 2027 commentary in February following Q4 results; currently pointing investors to September Essential announcement materials for 2027 outlook.

Miscellaneous:

• Free Cash Flow: Q3 FCF conversion was 68% ($35M); YTD FCF up $50M YoY. Q4 leverage expected to increase by ~0.5x upon transaction close.
• SG&A: Expense phasing (heavier in Q1, softer in Q3 due to international markets) contributed to unexpected leverage in Q3; no significant one-time items identified.
• Tax Rate: Q3 effective tax rate was 23%.
• Net Leverage: Exited quarter at 2.9x, below annual goal; range maintained at 2.5–3.5x post-acquisition.